Cutler Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Cutler Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,100	Closed	-$4K	–	4428
2023 Q2	$4K	Buy	+1,100	New	+$26.4K	﹤0.01%	2781
2022 Q2	–	Sell	-4,100	Closed	-$2K	–	5802
2022 Q1	$2K	Buy	+4,100	New	+$221K	﹤0.01%	4800
2021 Q4	–	Sell	-17,300	Closed	-$2K	–	6236
2021 Q3	$2K	Buy	17,300 +14,600	+541%	+$842K	﹤0.01%	5130
2021 Q2	$7K	Buy	+2,700	New	+$145K	﹤0.01%	4242

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cutler Group's ZNTL Position: Q1 2024 in Review

Cutler Group reduced its Zentalis Pharmaceuticals (ZNTL) stake by 33% in Q1 2024, selling an estimated $4.13K and leaving 600 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Cutler Group first reported a position in ZNTL in Q3 2021 and has held it in 4 quarters since. The position peaked at $603K in Q3 2021. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

Cutler Group held 600 shares of Zentalis Pharmaceuticals worth $9K as of Q1 2024.
Cutler Group sold 300 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $4.13K.
Zentalis Pharmaceuticals made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1353 holding.
Cutler Group first reported a position in Zentalis Pharmaceuticals in Q3 2021 and has held it in 4 quarters since.
Cutler Group's Zentalis Pharmaceuticals position peaked at $603K in Q3 2021.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.